IN2014DN10801A - - Google Patents
Info
- Publication number
- IN2014DN10801A IN2014DN10801A IN10801DEN2014A IN2014DN10801A IN 2014DN10801 A IN2014DN10801 A IN 2014DN10801A IN 10801DEN2014 A IN10801DEN2014 A IN 10801DEN2014A IN 2014DN10801 A IN2014DN10801 A IN 2014DN10801A
- Authority
- IN
- India
- Prior art keywords
- inhibitor
- imatinib
- gist
- therapy
- fgfr
- Prior art date
Links
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 abstract 3
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 abstract 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 abstract 2
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 abstract 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 abstract 2
- 229960002411 imatinib Drugs 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 229940124204 C-kit inhibitor Drugs 0.000 abstract 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002250 progressing effect Effects 0.000 abstract 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 abstract 1
- 229960001796 sunitinib Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261670168P | 2012-07-11 | 2012-07-11 | |
| PCT/US2012/061535 WO2013063003A1 (en) | 2011-10-28 | 2012-10-24 | Method of treating gastrointestinal stromal tumors |
| PCT/US2013/036273 WO2014011284A1 (en) | 2012-07-11 | 2013-04-12 | Method of treating gastrointestinal stromal tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN10801A true IN2014DN10801A (pt) | 2015-09-04 |
Family
ID=49916465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN10801DEN2014 IN2014DN10801A (pt) | 2012-07-11 | 2013-04-12 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150202203A1 (pt) |
| EP (1) | EP2872142A1 (pt) |
| JP (1) | JP2015522070A (pt) |
| KR (1) | KR20150036014A (pt) |
| CN (1) | CN104427986A (pt) |
| AU (1) | AU2013289175A1 (pt) |
| BR (1) | BR112015000349A2 (pt) |
| CA (1) | CA2878251A1 (pt) |
| IN (1) | IN2014DN10801A (pt) |
| MX (1) | MX2015000457A (pt) |
| RU (1) | RU2015104537A (pt) |
| WO (1) | WO2014011284A1 (pt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| SG10201610416TA (en) | 2012-06-13 | 2017-01-27 | Incyte Corp | Substituted tricyclic compounds as fgfr inhibitors |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| SI2986610T1 (en) | 2013-04-19 | 2018-04-30 | Incyte Holdings Corporation | Bicyclic heterocycles as inhibitors of FGFR |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MX2020004108A (es) | 2015-02-20 | 2022-01-03 | Incyte Corp | Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr). |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| AU2016385839B2 (en) * | 2016-01-11 | 2021-05-27 | Merck Patent Gmbh | Quinolin-2-one derivatives |
| WO2018204794A1 (en) | 2017-05-05 | 2018-11-08 | Csp Technologies, Inc. | Container having child-resistant senior-friendly features and method of using and making same |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| WO2019213544A2 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| TW201946630A (zh) | 2018-05-04 | 2019-12-16 | 美商英塞特公司 | Fgfr抑制劑之鹽 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP4031145A4 (en) * | 2019-09-06 | 2023-07-26 | Mantra Bio, Inc. | EXTRACELLULAR VESICLE FENRETINIDE COMPOSITIONS, EXTRACELLULAR VESICLE C-KIT INHIBITOR COMPOSITIONS, METHOD OF PREPARATION AND USES THEREOF |
| IL291901A (en) | 2019-10-14 | 2022-06-01 | Incyte Corp | Bicyclyl heterocycles as fgr suppressors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2021113462A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| US20230097907A1 (en) | 2020-01-27 | 2023-03-30 | Mantra Bio, Inc. | Non-naturally occurring vesicles comprising a chimeric vesicle localization moiety, methods of making and uses thereof |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| US20030028018A1 (en) | 2000-09-11 | 2003-02-06 | Chiron Coporation | Quinolinone derivatives |
| EA006711B1 (ru) | 2000-09-11 | 2006-02-24 | Чирон Корпорейшн | Хинолиноновые производные в качестве ингибиторов тирозинкиназы |
| GB0202873D0 (en) | 2002-02-07 | 2002-03-27 | Novartis Ag | Organic compounds |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| ITTV20030095A1 (it) | 2003-07-14 | 2005-01-15 | Asolo Spa | Calzatura con sottopiede composito. |
| WO2005046589A2 (en) | 2003-11-07 | 2005-05-26 | Chiron Corporation | Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| DK1885187T3 (da) | 2005-05-13 | 2013-12-09 | Novartis Ag | Fremgangsmåde til behandling af lægemiddelresistent cancer |
| KR101368519B1 (ko) | 2005-05-23 | 2014-02-27 | 노파르티스 아게 | 결정형 및 기타 형태의 4-아미노-5-플루오로-3-［6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일］-1ｈ-퀴놀린-2-온 락트산염 |
| GT200600316A (es) | 2005-07-20 | 2007-04-02 | Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. | |
| GT200600315A (es) | 2005-07-20 | 2007-03-19 | Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida | |
| EP1957074B1 (en) | 2005-11-29 | 2014-03-19 | Novartis AG | Formulations of quinolinones |
| EP1923053A1 (en) | 2006-09-27 | 2008-05-21 | Novartis AG | Pharmaceutical compositions comprising nilotinib or its salt |
| AR070924A1 (es) | 2008-03-19 | 2010-05-12 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona |
| JP5351254B2 (ja) | 2008-05-23 | 2013-11-27 | ノバルティス アーゲー | キノキサリン−およびキノリン−カルボキシアミド誘導体 |
| UY33472A (es) | 2010-06-30 | 2012-01-31 | Novartis Ag | ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?. |
| JP2014532647A (ja) * | 2011-10-28 | 2014-12-08 | ノバルティス アーゲー | 消化管間質腫瘍を治療する方法 |
-
2013
- 2013-04-12 CN CN201380037065.7A patent/CN104427986A/zh active Pending
- 2013-04-12 WO PCT/US2013/036273 patent/WO2014011284A1/en active Application Filing
- 2013-04-12 AU AU2013289175A patent/AU2013289175A1/en not_active Abandoned
- 2013-04-12 CA CA 2878251 patent/CA2878251A1/en not_active Abandoned
- 2013-04-12 MX MX2015000457A patent/MX2015000457A/es unknown
- 2013-04-12 JP JP2015521607A patent/JP2015522070A/ja active Pending
- 2013-04-12 KR KR20157000335A patent/KR20150036014A/ko not_active Application Discontinuation
- 2013-04-12 IN IN10801DEN2014 patent/IN2014DN10801A/en unknown
- 2013-04-12 EP EP13718720.9A patent/EP2872142A1/en not_active Withdrawn
- 2013-04-12 RU RU2015104537A patent/RU2015104537A/ru unknown
- 2013-04-12 US US14/413,045 patent/US20150202203A1/en not_active Abandoned
- 2013-04-12 BR BR112015000349A patent/BR112015000349A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN104427986A (zh) | 2015-03-18 |
| KR20150036014A (ko) | 2015-04-07 |
| AU2013289175A1 (en) | 2015-01-22 |
| WO2014011284A1 (en) | 2014-01-16 |
| MX2015000457A (es) | 2015-04-08 |
| US20150202203A1 (en) | 2015-07-23 |
| RU2015104537A (ru) | 2016-08-27 |
| CA2878251A1 (en) | 2014-01-16 |
| JP2015522070A (ja) | 2015-08-03 |
| BR112015000349A2 (pt) | 2017-06-27 |
| EP2872142A1 (en) | 2015-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN10801A (pt) | ||
| TN2014000093A1 (en) | Method of treating gastrointestinal stromal tumors | |
| IL291000A (en) | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for cancer therapy | |
| PH12017501817A1 (en) | Heterocyclic compounds as lsd1 inhibitors | |
| HK1207861A1 (en) | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1 | |
| MX2020003702A (es) | Ciclopropilaminas como inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
| HRP20150692T8 (en) | Substituted benzopyrazin derivatives as fgfr kinase inhibitors for the treatment of cancer diseases | |
| HK1210174A1 (en) | Serine threonine kinase inhibitors for the treatment of hyperproliferativediseases | |
| EP3094752A4 (en) | Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity | |
| PT3418281T (pt) | Pirazolo[1,5-a]pirimidinas úteis como inibidores da quinase atr para o tratamento de doenças de cancro | |
| HK1206743A1 (en) | 4-hydroxy-isoquinoline compounds as hif hydroxylase inhibitors hif 4-- | |
| MX355728B (es) | Inhibidores de cinasas. | |
| IL232128B (en) | Tor kinase inhibitors for cancer treatment | |
| JO2788B1 (en) | Amido phenoxyendazole compounds beneficial as C-MET inhibitors | |
| JO3450B1 (ar) | أشكال جرعات تحرير جديدة معدلة لمثبطات زانثين اوكسيدوريدوكتيز أو مثبطات زانثين اوكسيديز | |
| IL212142A0 (en) | Heterocyclically substituted aryl compounds as hif inhibitors | |
| MX337722B (es) | Uso de nuevos inhibidores de pan-cdk para tratar tumores. | |
| HK1205500A1 (en) | Kinase inhibitors for the treatment of cancer | |
| SG11201601150WA (en) | Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors | |
| EP2897607A4 (en) | BETA-HYDROLASE INHIBITORS FOR THE TREATMENT OF CANCER | |
| IL215199A0 (en) | Thia-triaza-cyclopentazulenes as pi3-kinases inhibitors for the treatment of cancer | |
| TN2011000013A1 (en) | Amidophenoxyindazoles useful as inhibitors of c-met | |
| AU2012901199A0 (en) | Kinase inhibitors for the Treatment of Cancer |